Here is Phase II data, Drug continue to help after 4 year. (This is back in 2009 but as I always say facts & fundamental does not change, ofcourse Analyst opionion does change even with slight negative news) If we get similar result from Phase III trial we will go much higher. Another intesting thing is After 52 Week, 345 out of 449 continue on antoher 24 week extention and 296 continue 4 year study. Very small dropout rate. If patients not seeing benefit dropout rate would be much higher. I normally don't bet against market trend, but more I study, I find Analysts might have their own agenda. I think it worth wait atleast another 6 month before reach conclusion on success or failure.